CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, D0
Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Amended material disclosure
FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Exhibit 99.1
Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Investor Presentation
Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Q3
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities